Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.

ABSTRACT:

Background and aim

This study aimed to determine the efficacy and safety of vedolizumab treatment with or without concomitant immunomodulator use in Japanese patients with moderate-to-severe ulcerative colitis.

Methods

Among enrolled patients in a phase 3 study conducted in Japan (clinicaltrials.gov, NCT02039505), data from patients allocated to 300-mg intravenous vedolizumab for induction and maintenance phases were used for this exploratory analysis. Efficacy endpoints were clinical response, clinical remission, and mucosal healing at week 10 and clinical remission and mucosal healing at week 60, and disease worsening and treatment failure during the maintenance phase.

Results

At week 10, the differences in clinical response, clinical remission, and mucosal healing

SUBMITTER: Naganuma M 

PROVIDER: S-EPMC9293068 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature